MA46355A - Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide - Google Patents

Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide

Info

Publication number
MA46355A
MA46355A MA046355A MA46355A MA46355A MA 46355 A MA46355 A MA 46355A MA 046355 A MA046355 A MA 046355A MA 46355 A MA46355 A MA 46355A MA 46355 A MA46355 A MA 46355A
Authority
MA
Morocco
Prior art keywords
malignities
dimethoxyquinolin
dicarboxamide
genitourinary
cyclopropane
Prior art date
Application number
MA046355A
Other languages
English (en)
French (fr)
Inventor
Andrea B Apolo
Original Assignee
The Us Secretary Department Of Health And Human Services Office Of Technology Transfer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Us Secretary Department Of Health And Human Services Office Of Technology Transfer filed Critical The Us Secretary Department Of Health And Human Services Office Of Technology Transfer
Publication of MA46355A publication Critical patent/MA46355A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/868—Vaccine for a specifically defined cancer kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA046355A 2016-09-27 2017-09-27 Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide MA46355A (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662400481P 2016-09-27 2016-09-27
US201762457952P 2017-02-12 2017-02-12
US201762459340P 2017-02-15 2017-02-15
US201762552296P 2017-08-30 2017-08-30

Publications (1)

Publication Number Publication Date
MA46355A true MA46355A (fr) 2019-08-07

Family

ID=60190916

Family Applications (1)

Application Number Title Priority Date Filing Date
MA046355A MA46355A (fr) 2016-09-27 2017-09-27 Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide

Country Status (7)

Country Link
US (2) US20210275515A1 (OSRAM)
EP (1) EP3518928A1 (OSRAM)
JP (1) JP2019529476A (OSRAM)
AU (1) AU2017336547A1 (OSRAM)
CA (1) CA3038500A1 (OSRAM)
MA (1) MA46355A (OSRAM)
WO (1) WO2018064191A1 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018160841A1 (en) 2017-03-01 2018-09-07 Genentech, Inc. Diagnostic and therapeutic methods for cancer
SG11202006921PA (en) 2018-01-26 2020-08-28 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
CN113292537B (zh) 2018-06-15 2024-04-05 汉达癌症医药责任有限公司 激酶抑制剂的盐类及其组合物
CN113196061A (zh) * 2018-10-18 2021-07-30 豪夫迈·罗氏有限公司 肉瘤样肾癌的诊断和治疗方法
US20230301979A1 (en) * 2020-07-31 2023-09-28 Exelixis, Inc. Combinations for the treatment of cancer
CA3202761A1 (en) * 2020-11-25 2022-06-02 Nanocopoeia, Llc Amorphous cabozantinib particles and uses thereof
US20220280500A1 (en) * 2021-02-19 2022-09-08 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
US20220387418A1 (en) * 2021-02-19 2022-12-08 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
US11590122B2 (en) 2021-02-19 2023-02-28 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
US20220362235A1 (en) * 2021-02-19 2022-11-17 Slayback Pharma Llc Pharmaceutical compositions of cabozantinib
CN120417903A (zh) 2023-01-31 2025-08-01 汉达癌症医药责任有限公司 改良的卡博替尼组合物及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2744997A1 (en) 2003-09-26 2005-04-07 Exelixis, Inc. C-met modulators and method of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
EP2593090B1 (en) 2010-07-16 2021-10-13 Exelixis, Inc. C-met modulator pharmaceutical compositions
EA033513B1 (ru) 2011-02-10 2019-10-31 Exelixis Inc Способы получения хинолиновых соединений и фармацевтических композиций, содержащих такие соединения

Also Published As

Publication number Publication date
US20210275515A1 (en) 2021-09-09
AU2017336547A1 (en) 2019-05-02
EP3518928A1 (en) 2019-08-07
JP2019529476A (ja) 2019-10-17
US20230130243A1 (en) 2023-04-27
WO2018064191A1 (en) 2018-04-05
WO2018064191A8 (en) 2019-04-18
CA3038500A1 (en) 2018-04-05

Similar Documents

Publication Publication Date Title
MA46355A (fr) Procédé de traitement du carcinome urothélial et d'autres malignités génito-urinaires à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy)-phényl)-n'-(4-fluorophényl)cyclopropane -1,1-dicarboxamide
DK4206216T3 (da) Adeno-associerede virusvarianter og fremgangsmåder til brug deraf
IL257663B (en) Oral care compositions and methods of use
EP3313404A4 (en) THERAPEUTIC COMPOSITIONS, COMBINATIONS AND METHODS OF USE
DK3426781T3 (da) Mikro-rna'er og fremgangsmåder til anvendelse deraf
EP3471780A4 (en) TREATMENT OF AMD WITH AAV2 VARIANT WITH AFLIBERCEPT
EP3368560A4 (en) CPG REDUCED FACTOR VIII VARIATIONS, COMPOSITIONS AND METHODS AND USES FOR THE TREATMENT OF HEMOSTASIS
DK3445388T3 (da) Materialer og fremgangsmåder til behandling af hæmoglobinopatier
IL256805B (en) Compounds -4-)-n aryl(phenyl)-2-(4-(1,1-(difluoroalkyl(phenyl)-acetamide and their use for the treatment of diseases modulated by rorgt
DK3735295T3 (da) Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser
EP3344274A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES RELATED TO ABNORMAL INFLAMMATORY REACTIONS
DK3277815T3 (da) Oligonukleotidforbindelser til behandling af præeklampsi og andre angiogene lidelser
HUE052468T2 (hu) Arginázgátlók és terápiás alkalmazásaik
MA44672A (fr) Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
DK3405215T3 (da) Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
EP3320093A4 (en) COMPOSITIONS AND METHODS FOR IDENTIFYING, EVALUATING, PREVENTING AND TREATING CANCER USING SLNCR ISOFORMS
DK3262037T3 (da) Nyt quinolinderivat til anvendelse til behandling og forebyggelse af virusinfektioner
EP3407900A4 (en) DEVICE FOR TOPICAL APPLICATION OF STAIN OXIDE AND METHOD
EP3374350A4 (en) HYDROXYPYRIDINONE- AND HYDROXYPYRIMIDINONE-BASED COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
HUE060496T2 (hu) Terápiás vegyületek és készítmények szociális zavarok és szerhasználati zavarok kezelésére
EP3706743A4 (en) Modified ligand-gated ion channels and methods of use
IL264070A (en) Methods and compositions for treatment of disorders and diseases involving rdh12
EP3416665A4 (en) FORMULATION AND METHOD FOR USE
EP3500278A4 (en) METHOD AND COMPOSITIONS FOR TREATING DISEASES WITH RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS
EP3411128A4 (en) CONTINUOUS ROTARY PLATE FILTER AND METHOD OF USE THEREOF